741 results on '"Dent, R."'
Search Results
2. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
3. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
4. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
5. Proverbial Language in English Drama Exclusive of Shakespeare, 1495-1616 : An Index
6. John Webster's Borrowing
7. Characterizing a Clinical Trial – Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction
8. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
9. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
10. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
11. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study.
12. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
13. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
14. A285 CHANGE IN ALT DURING MODIFIED OPTIFAST WEIGHT LOSS PROGRAM IN INDIVIDUALS AT RISK FOR NON-ALCOHOLIC FATTY LIVER DISEASE
15. Cytokinin O-glucosides : neglected products of cytokinin metabolism
16. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
17. Survival of women with inflammatory breast cancer: a large population-based study
18. Targeting triple-negative breast cancer: optimising therapeutic outcomes
19. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
20. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
21. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
22. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
23. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
24. Impact of Smoking Status on Weight Loss and Cardiovascular Risk Factors
25. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
26. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
27. The Lakes of Kenya and Uganda: Discussion
28. Imagination in A Midsummer Night's Dream
29. Naturally occurring R225W mutation of the gene encoding AMP-activated protein kinase (AMPK)γ3 results in increased oxidative capacity and glucose uptake in human primary myotubes
30. Increased susceptibility to oxidative damage in post-diabetic human myotubes
31. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
32. PNS130 The Appropriateness of EQ-5D across Conditions: A Review of the Literature and NICE Technology Appraisals
33. PRO89 The Use of EQ-5D in NICE Highly Specialised Technologies Evaluations: A Review of Published Guidance
34. 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation
35. 13P A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
36. 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
37. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
38. 21 Prophylactic management of cholelithiasis in bariatric patients: Is routine cholecystectomy warranted?
39. 359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
40. 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
41. 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
42. 7. PD-L1 in triple negative breast cancer – optimal testing for therapeutic efficacy
43. The fundamental mechanism of laser-induced damage in optical components for ultrashort-pulse laser systems
44. PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW
45. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
46. Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
47. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
48. IMPROVEMENTS IN BACK PAIN FOLLOWING ENROLMENT IN A MULTIDISCIPLINARY WEIGHT MANAGEMENT PROGRAMME - EARLY RESULTS
49. Prediction and use of impedance matrices for eddy-current problems
50. Hamlet: Scourge and Minister
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.